Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
98.80
-3.72 (-3.63%)
Streaming Delayed Price
Updated: 12:41 PM EST, Dec 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
24
25
Next >
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
↗
February 22, 2024
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.
Via
Chartmill
Exit Now! 3 Biotech Stocks to Sell in February 2024
↗
February 21, 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
Via
InvestorPlace
Incyte to Present at Upcoming Investor Conference
February 15, 2024
From
Incyte
Via
Business Wire
The Analyst Verdict: Incyte In The Eyes Of 8 Experts
↗
February 14, 2024
Via
Benzinga
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D Priorities
February 13, 2024
From
Incyte
Via
Business Wire
NASDAQ:INCY is not too expensive for the growth it is showing.
↗
February 01, 2024
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing.
Via
Chartmill
Expert Ratings for Incyte
↗
December 13, 2023
Via
Benzinga
What's Up With Incyte Stock Lately?
↗
December 12, 2023
Incyte Corporation (NASDAQ: INCY) shares are trading higher on Tuesday. The stock has risen rapidly since Monday.
Via
Benzinga
Earnings Scheduled For February 13, 2024
↗
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Despite its impressive fundamentals, NASDAQ:INCY remains undervalued.
↗
February 12, 2024
INCYTE CORP (NASDAQ:INCY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via
Chartmill
Pancreatic Cancer Treatments Poised for Major Advances in 2024
February 07, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:INCY),(NASDAQ:TNGX),(NASDAQ:RYZB),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Novartis Agrees To Acquire German Blood Cancer-Drug Developer MorphoSys For €2.7B
↗
February 06, 2024
Novartis' €2.7 billion public takeover offer for MorphoSys, unlocking a promising oncology pipeline with pelabresib and tulmimetostat.
Via
Benzinga
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
↗
February 05, 2024
Novartis will add to its cancer treatment pipeline with via the German biotech.
Via
Investor's Business Daily
Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)
February 05, 2024
From
Incyte
Via
Business Wire
Why Is MorphoSys (MOR) Stock Up 50% Today?
↗
February 05, 2024
News of a potential takeout bid for any company usually leads to a big surge. That's what investors are seeing today with MOR stock.
Via
InvestorPlace
MorphoSys Stock Soars After Report Says Novartis To Acquire Cancer-Drug Developer
↗
February 05, 2024
Novartis is in advanced talks to acquire MorphoSys and appears to be beating out Incyte Corporation which has also made an offer to acquire MorphoSys. MorphoSys produces a lymphoma drug, Monjuvi, sold...
Via
Benzinga
5 top healthcare stocks for earnings growth in 2024
January 25, 2024
2024 holds promise for healthcare stocks, with Humana, Elevance, and others expected to boost earnings, as analysts say many industry pressures have been removed.
Via
MarketBeat
Incyte to Report Fourth Quarter and Year-End 2023 Financial Results
January 23, 2024
From
Incyte
Via
Business Wire
NASDAQ:INCY is probably undervalued for the fundamentals it is displaying.
↗
January 19, 2024
For those who appreciate value investing, INCYTE CORP (NASDAQ:INCY) is a compelling option with its solid fundamentals.
Via
Chartmill
3 Pharma Stocks Could Be the Pills Your Portfolio Needs
↗
January 18, 2024
These large-cap pharma stocks offer growth and value with existing medicines, deep pipelines and reasonable valuations.
Via
InvestorPlace
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
↗
January 10, 2024
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to
Via
Benzinga
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
↗
January 10, 2024
Investors seeking growth at a reasonable cost should explore INCYTE CORP (NASDAQ:INCY).
Via
Chartmill
Incyte Highlights Growth Opportunities and Provides Business Updates at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
Incyte
Via
Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
↗
December 28, 2023
In a market where value is scarce, INCYTE CORP (NASDAQ:INCY) offers a refreshing opportunity with its solid fundamentals.
Via
Chartmill
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
↗
December 19, 2023
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.
Via
Chartmill
AI Meets Biotech: 3 Top Stocks Transforming Medical Science
↗
December 16, 2023
The AI revolution is bringing big gains to biotechnology, including drugs, antibodies, and synthetic biology.
Via
InvestorPlace
Topics
Artificial Intelligence
The 3 Most Undervalued Biotech Stocks to Buy in December
↗
December 15, 2023
Biotech is an increasing area of interest in the financial markets, line your portfolio up with these winning biotech stocks.
Via
InvestorPlace
Incyte to Present at Upcoming Investor Conferences
December 12, 2023
From
Incyte
Via
Business Wire
Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease
December 10, 2023
From
Incyte and Syndax Pharmaceuticals
Via
Business Wire
S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets
↗
December 07, 2023
Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).
Via
Benzinga
Topics
Stocks
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
